Drugs / PAN-NeoVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07560943 | Apr 2026 → Apr 2027 expected | cancer | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAN-NeoVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07560943 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA vaccine” NCT07560943 ↗ |
| Route | Other | “administered by intratumoral injection” NCT07560943 ↗ |